The recent White House meeting with leaders from American pharmaceutical companies sought their help in solving the coronavirus that originated in Wuhan, China and is currently gripping the globe. The meeting was part of the U.S. government marshaling our nation’s private and public medical research and development (R&D) resources in a race to create therapeutics, vaccines, diagnostic tools and cures. The Wall Street Journal has noted that “a core U.S. strength is the breadth of its private medical resources. That’s on display now as the government is calling on private actors to buttress the federal response.” Ironically, the same U.S. government urging the same private industry whose intellectual property rights enable it to develop medical miracles to help is targeting American pharmaceutical firms with a number of IP-killing policy proposals. One such bad idea comes from the Food & Drug Administration in a rulemaking titled “Importation of Prescription Drugs Proposed Rule (Docket No. FDA-2019-N-5711).”
Recent Posts
- Other Barks & Bites for Friday, October 25: Microsoft CEO Asks for Changes in Copyright Law; Report Finds 22% Growth in Semiconductor Patent Filings; and Former OpenAI Employee Claims Company Breaks Copyright Law
- Federal Circuit Vacates District Court’s Denial of Antisuit Injunction in FRAND Case
- SCOTUS Petitioner Says Newman’s Absence from the CAFC Deprived It of a Fair Shot in Eligibility Case
- Helping Small Business with Innovation and IP | IPWatchdog Unleashed
- How Commercial General Liability Policies’ ‘Coverage B’ Can Help Mitigate IP Losses